4,718 results match your criteria oseltamivir


A Unique Case of Spontaneous Pneumomediastinum in a Patient With COVID-19 and Influenza Coinfection.

J Investig Med High Impact Case Rep 2021 Jan-Dec;9:23247096211016228

Lovelace Medical Center, Albuquerque, NM, USA.

Spontaneous pneumomediastinum is reported in patients with coronavirus disease-2019 (COVID-19) and influenza infection independently, usually associated with noninvasive and mechanical ventilation. We report a case of spontaneous pneumomediastinum in a patient with COVID-19 and influenza coinfection. A 58-year-old male admitted with shortness of breath, diagnosed with COVID-19 and influenza infection. Read More

View Article and Full-Text PDF

Macrocyclic peptides exhibit antiviral effects against influenza virus HA and prevent pneumonia in animal models.

Nat Commun 2021 May 11;12(1):2654. Epub 2021 May 11.

Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.

Most anti-influenza drugs currently used, such as oseltamivir and zanamivir, inhibit the enzymatic activity of neuraminidase. However, neuraminidase inhibitor-resistant viruses have already been identified from various influenza virus isolates. Here, we report the development of a class of macrocyclic peptides that bind the influenza viral envelope protein hemagglutinin, named iHA. Read More

View Article and Full-Text PDF

Inhibition effects of eight anti-coronavirus drugs on glycosides metabolism and glycosidases in human gut microflora.

Pharmazie 2021 05;76(5):195-201

Department of Orthopaedics, Guangzhou Red Cross Hospital, Jinan University, Guangzhou, China;, Email:

The effects of eight oral anti-coronavirus drugs (lopinavir, ritonavir, chloroquine, darunavir, ribavirin, arbidol, favipiravir, oseltamivir) on the metabolism of four specific glycosides (polydatin, geniposide, quercitrin, glycyrrhizin) and on the activities of three major glycosidases (β-glucosidase, α-rhamnosidase, β-glucuronidase) from gut microflora were explored and determined by LC-MS/MS. The metabolism of polydatin, geniposide, quercitrin and glycyrrhizin was significantly inhibited by one or several anti-coronavirus drugs of 100 μM around 1 h and 4 h (P<0.05), among which darunavir could strongly reduce the production of genipin (70. Read More

View Article and Full-Text PDF

A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics.

Nat Biomed Eng 2021 May 3. Epub 2021 May 3.

Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.

The rapid repurposing of antivirals is particularly pressing during pandemics. However, rapid assays for assessing candidate drugs typically involve in vitro screens and cell lines that do not recapitulate human physiology at the tissue and organ levels. Here we show that a microfluidic bronchial-airway-on-a-chip lined by highly differentiated human bronchial-airway epithelium and pulmonary endothelium can model viral infection, strain-dependent virulence, cytokine production and the recruitment of circulating immune cells. Read More

View Article and Full-Text PDF

Inhibitory effects of aprotinin on influenza A and B viruses in vitro and in vivo.

Sci Rep 2021 May 3;11(1):9427. Epub 2021 May 3.

Department of Pharmacy, College of Pharmacy, Korea University, 2511 Sejong-ro, Sejong, 30019, Republic of Korea.

Influenza viruses cause significant morbidity and mortality worldwide. Long-term or frequent use of approved anti-influenza agents has resulted in drug-resistant strains, thereby necessitating the discovery of new drugs. In this study, we found aprotinin, a serine protease inhibitor, as an anti-influenza candidate through screening of compound libraries. Read More

View Article and Full-Text PDF

Cell culture-based production and in vivo characterization of purely clonal defective interfering influenza virus particles.

BMC Biol 2021 May 3;19(1):91. Epub 2021 May 3.

Otto-von-Guericke-University Magdeburg, Chair of Bioprocess Engineering, Magdeburg, Germany.

Background: Infections with influenza A virus (IAV) cause high morbidity and mortality in humans. Additional to vaccination, antiviral drugs are a treatment option. Besides FDA-approved drugs such as oseltamivir or zanamivir, virus-derived defective interfering (DI) particles (DIPs) are considered promising new agents. Read More

View Article and Full-Text PDF

Oseltamivir treatment of influenza A and B infections in infants.

Influenza Other Respir Viruses 2021 May 3. Epub 2021 May 3.

Department of Pediatrics, University of Turku, Turku University Hospital, Turku, Finland.

Background: Oseltamivir treatment is currently the only way of managing influenza in young infants for whom influenza vaccines are not licensed, but little data exist on the effectiveness of the treatment in this age group.

Methods: In a prospective study, we enrolled 431 newborn infants and followed them up for 10 months during their first respiratory season (September 2017-June 2018). During each respiratory illness, we examined the infants and obtained nasopharyngeal specimens for determination of the viral etiology. Read More

View Article and Full-Text PDF

An influenza A(H5N8) virus isolated during an outbreak at a poultry farm in Russia in 2017 has an N294S substitution in the neuraminidase and shows reduced susceptibility to oseltamivir.

Antiviral Res 2021 Apr 29;191:105079. Epub 2021 Apr 29.

State Research Center of Virology and Biotechnology "Vector" Rospotrebnadzor, Koltsovo, Novosibirsk Region, 630559, Russian Federation.

This study aimed to assess the antiviral susceptibility of influenza A(H5N8) viruses isolated in Russia in 2014-2018. Genetic analysis of 57 Russian isolates with full genome sequences did not find any markers of reduced susceptibility to baloxavir. Only one strain bore an amino acid substitution associated with adamantane resistance (M2-S31N). Read More

View Article and Full-Text PDF

What if COVID-19 affects the child: which weapons and how to use them.

Eur Rev Med Pharmacol Sci 2021 Apr;25(8):3325-3337

School of Pediatrics, University of Cagliari, Cagliari, Italy.

Since the reports in Wuhan (China), in December 2019, of the first cluster of cases of pneumonia caused by the new Coronavirus called 2019-nCoV or SARS-CoV-2, there has been a pandemic spread of the infection. By now, we have no specific therapy to counteract this emergency. The latest epidemiological data suggest that children are just as likely as adults to get infected by the virus. Read More

View Article and Full-Text PDF

Design, Synthesis, Biological Evaluation and In Silico Studies of Pyrazole-Based NH-Acyl Oseltamivir Analogues as Potent Neuraminidase Inhibitors.

Pharmaceuticals (Basel) 2021 Apr 16;14(4). Epub 2021 Apr 16.

State Key Laboratory of Chemical Biology and Drug Discovery, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Kowloon, Hong Kong, China.

Oseltamivir represents one of the most successful neuraminidase (NA) inhibitors in the current anti-influenza therapy. The 150-cavity of NA was identified as an additional binding pocket, and novel NA inhibitors have been designed to occupy the 150-cavity based on the structure information of oseltamivir carboxylate () in complex with NA. In this study, a series of C-5-NH-acyl derivatives of containing the pyrazole moiety were synthesized. Read More

View Article and Full-Text PDF

Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance.

Viruses 2021 04 6;13(4). Epub 2021 Apr 6.

State Key Laboratory of Respiratory Diseases, Guangzhou Medical University, 195 Dongfengxi Rd, Guangzhou 510182, China.

Hemagglutinin and neuraminidase, which constitute the glycoprotein spikes expressed on the surface of influenza A and B viruses, are the most exposed parts of the virus and play critical roles in the viral lifecycle. As such, they make prominent targets for the immune response and antiviral drugs. Neuraminidase inhibitors, particularly oseltamivir, constitute the most commonly used antivirals against influenza viruses, and they have proved their clinical utility against seasonal and emerging influenza viruses. Read More

View Article and Full-Text PDF

Maternal and Perinatal Outcomes of Influenza in Pregnancy after Treatment with Oseltamivir.

J Glob Infect Dis 2021 Jan-Mar;13(1):20-26. Epub 2021 Jan 29.

Global Health Center, Cincinnati Children's Hospital, Cincinnati, OH, USA.

Context: Influenza infection in pregnancy causes 4%-8% case fatality and five times more perinatal mortality. Influenza is a major contributor to mortality in developing countries; however, the morbidity has largely been underestimated. Public health interventions for prevention are also lacking. Read More

View Article and Full-Text PDF
January 2021

Nanoparticle composite TPNT1 is effective against SARS-CoV-2 and influenza viruses.

Sci Rep 2021 04 22;11(1):8692. Epub 2021 Apr 22.

Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, No. 7, Chung-Shan South Rd., Taipei, 10002, Taiwan.

A metal nanoparticle composite, namely TPNT1, which contains Au-NP (1 ppm), Ag-NP (5 ppm), ZnO-NP (60 ppm) and ClO (42.5 ppm) in aqueous solution was prepared and characterized by spectroscopy, transmission electron microscopy, dynamic light scattering analysis and potentiometric titration. Based on the in vitro cell-based assay, TPNT1 inhibited six major clades of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with effective concentration within the range to be used as food additives. Read More

View Article and Full-Text PDF

Influenza-associated hemolytic uremic syndrome: The pathogenic role of the virus.

Clin Nephrol Case Stud 2021 16;9:45-48. Epub 2021 Apr 16.

Pediatric Nephrology, Dialysis, and Transplantation Department of Woman and Child Health, University of Padova, Padova.

A 3-year-old girl came to our attention for fever and upper respiratory tract infection associated with thrombocytopenia, non-immune hemolytic anemia, and acute kidney injury (AKI). Complete blood count and renal function slowly normalized, with no need for dialysis. She was always normotensive with valid diuresis; her neurological status also rapidly improved. Read More

View Article and Full-Text PDF

[Influenza A-associated acute necrotizing encephalopathy].

Rev Chil Pediatr 2020 Dec 24;91(6):941-946. Epub 2020 Sep 24.

Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Introduction: Acute necrotizing encephalopathy of childhood (ANEC) is a rare disease characterized by alteration of consciousness and multiple symmetric brain lesions mainly involving the thalamus. It presents a high mortality rate and severe sequelae.

Objective: To describe a school-age patient with influenza A-related ANEC with favorable evolution. Read More

View Article and Full-Text PDF
December 2020

Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta.

PLoS One 2021 16;16(4):e0250147. Epub 2021 Apr 16.

Faculty of Pharmacy, Universitas 17 Agustus 1945, Jakarta, Indonesia.

Background: Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is a virus that causes COVID-19, which has become a worldwide pandemic. However, until now, there is no vaccine or specific drug to prevent or treat COVID-19.

Objectives: To find out the effective treatment as an antiviral agent for COVID-19, to determine the correlation between sociodemography with clinical outcomes and duration of treatment, and to determine the relationship between comorbidities with clinical outcomes and duration of treatment for COVID-19 patients. Read More

View Article and Full-Text PDF

Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials.

Expert Rev Clin Pharmacol 2021 Apr 26:1-18. Epub 2021 Apr 26.

CIBER De Enfermedades Respiratorias (CIBERES), Instituto Salud Carlos III, Madrid, Spain.

: Scarce evidence verifying the clinical impact of baloxavir on influenza complications is found.: PubMed, Cochrane Library, and Web of Science databases were searched through December 2020. Randomized-controlled trials (RCT) that enrolled patients with laboratory-confirmed influenza receiving neuraminidase inhibitors (NAI) or baloxavir comparing to placebo were assessed. Read More

View Article and Full-Text PDF

Rapid Enantioselective and Diastereoconvergent Hybrid Organic/Biocatalytic Entry into the Oseltamivir Core.

J Org Chem 2021 May 15;86(9):6494-6503. Epub 2021 Apr 15.

Department of Chemistry, University of Nebraska, Lincoln, Nebraska 68588, United States.

A formal synthesis of the antiviral drug (-)-oseltamivir (Tamiflu) has been accomplished starting from -anisic acid via a dissolving metal or electrochemical Birch reduction. The correct absolute stereochemistry is efficiently set through enzyme-catalyzed carbonyl reduction on the resultant racemic α,β-unsaturated ketone. A screen of a broad ketoreductase (KRED) library identified several that deliver the desired allylic alcohol with nearly perfect facial selectivity at the new center for each antipodal substrate, indicating that the enzyme also is able to completely override inherent diastereomeric bias in the substrate. Read More

View Article and Full-Text PDF

Detection of variants with reduced baloxavir marboxil and oseltamivir susceptibility in children with influenza A during the 2019-2020 influenza season.

J Infect Dis 2021 Apr 10. Epub 2021 Apr 10.

Department of Pediatrics, Fukushima Medical University, Fukushima, Japan.

Background: We aimed to detect influenza variants with reduced susceptibility to baloxavir marboxil (baloxavir) and oseltamivir and identify differences in the clinical course between children with and without these variants after anti-viral treatment.

Methods: During the 2019-2020 influenza season, we enrolled children with confirmed influenza A (20 treated with baloxavir and 16 with oseltamivir). We analyzed patients' sequential viral RNA loads and infectious virus titers, the drug susceptibilities of clinical isolates, and amino acid substitutions in the viral polymerase acidic protein subunits or neuraminidase. Read More

View Article and Full-Text PDF

The Impact of Immunization and Use of Oseltamivir on Influenza-Related Hospitalizations: A Population-Based Study.

J Prim Care Community Health 2021 Jan-Dec;12:21501327211005906

Hospital for Special Surgery, New York, NY, USA.

Background: As the COVID-19 pandemic continues into flu season, it is critical to minimize hospitalizations to maximize capacity and preserve critical care resources. We sought to identify risk factors for influenza-related hospitalization, specifically the role of immunization and oseltamivir prescriptions.

Methods: Patients with influenza diagnoses were identified from the MarketScan database (2014-2018). Read More

View Article and Full-Text PDF

Elderberry for prevention and treatment of viral respiratory illnesses: a systematic review.

BMC Complement Med Ther 2021 Apr 7;21(1):112. Epub 2021 Apr 7.

The Ottawa Hospital Research Institute (OHRI), Ottawa, Ontario, Canada.

Background: Elderberry has traditionally been used to prevent and treat respiratory problems. During the COVID-19 pandemic, there has been interest in elderberry supplements to treat or prevent illness, but also concern that elderberry might overstimulate the immune system and increase the risk of 'cytokine storm'. We aimed to determine benefits and harms of elderberry for the prevention and treatment of viral respiratory infections, and to assess the relationship between elderberry supplements and negative health impacts associated with overproduction of pro-inflammatory cytokines. Read More

View Article and Full-Text PDF

Differences in antibiotic and antiviral use in people with confirmed influenza: a retrospective comparison of rapid influenza PCR and multiplex respiratory virus PCR tests.

BMC Infect Dis 2021 Apr 7;21(1):321. Epub 2021 Apr 7.

Department of Infectious Diseases, Prince of Wales Hospital, Randwick, Sydney, NSW, Australia.

Background: Influenza is a highly contagious respiratory virus with clinical impacts on patient morbidity, mortality and hospital bed management. The effect of rapid nucleic acid testing (RPCR) in comparison to standard multiplex PCR (MPCR) diagnosis in treatment decisions is unclear. This study aimed to determine whether RPCR influenza testing in comparison to standard MPCR testing was associated with differences in antibiotic and antiviral (oseltamivir) utilisation and hospital length of stay in emergency department and inpatient hospital settings. Read More

View Article and Full-Text PDF

Oseltamivir-Induced Mania in a Patient With Influenza A.

Authors:
Eda Ferahkaya

Clin Neuropharmacol 2021 May-Jun 01;44(3):106-107

Department of Psychiatry, Konya Training and Research Hospital, University of Health Sciences, Konya, Turkey.

Abstract: Oseltamivir is an antiviral drug often preferred in treating viral infections. Its use has increased owing to annual influenza outbreaks and the COVID-19 pandemic. Although its adverse effects are often seen in the gastrointestinal system, it has other adverse effects that can prevent its use, for example, neuropsychiatric events. Read More

View Article and Full-Text PDF

Pharmacogenetics Approach for the Improvement of COVID-19 Treatment.

Viruses 2021 03 5;13(3). Epub 2021 Mar 5.

HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico.

The treatment of coronavirus disease 2019 (COVID-19) has been a challenge. The efficacy of several drugs has been evaluated and variability in drug response has been observed. Pharmacogenetics could explain this variation and improve patients' outcomes with this complex disease; nevertheless, several disease-related issues must be carefully reviewed in the pharmacogenetic study of COVID-19 treatment. Read More

View Article and Full-Text PDF

Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.

Sci Rep 2021 03 31;11(1):7282. Epub 2021 Mar 31.

Chest Department, Ain Shams University, Cairo, Egypt.

Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases. It was randomized-controlled open-label interventional phase 3 clinical trial [NCT04349241]. Read More

View Article and Full-Text PDF

COVID 19 infection in young patient with pectus excavatum

Rev Fac Cien Med Univ Nac Cordoba 2021 03 25;78(1):52-56. Epub 2021 Mar 25.

Hospital de Clínicas Dr. Manuela Quintela.

Introduction: The SARS-Cov-2 infection causing the COVID 19 disease mainly affects the respiratory system, in most cases presenting mild symptoms, however in patients with comorbidities such as pectus excavatum that cause an alteration in lung function, the disease It can be deadly.

Case Presentation: A 25-year-old male with a history of congenital pectus excavatum and scoliosis, with clinical of COVID 19 and confirmatory results of PCR, TC and Rx of the infection, begins with mild symptoms of affection in the upper respiratory tract, cough and odynophagia, that due to its basic anatomical alteration, progresses to SDRA, is treated with Oxygen Therapy, Ampicillin Sulbactam, Azithromycin, Oseltamivir, Lopinavir / Ritonavir, Hydroxychloroquine, Tiotropium, Paracetamol, Heparin and Omeprazole presenting a favorable evolution on the third day of hospitalization.

Conclusion: The case reflects what is known to date about the risk of severe complications that SARS-CoV-2 infection can present in patients with comorbidities or pathologies that alter lung function such as the pectus excavatum. Read More

View Article and Full-Text PDF

Insights on chronic immune thrombocytopenia pathogenesis: A bench to bedside update.

Blood Rev 2021 Mar 18:100827. Epub 2021 Mar 18.

Department of Hematology, Internal Medicine Division, Dr. Jose E. González University Hospital and School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico.

Immune thrombocytopenia (ITP) is a heterogeneous disease with an unpredictable course. Chronicity can develop in up to two-thirds of adults and 20-25% of children, representing a significant burden on patients' quality of life. Despite acceptable responses to treatment, precise etiology and pathophysiology phenomena driving evolution to chronicity remain undefined. Read More

View Article and Full-Text PDF

Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial.

Lancet Haematol 2021 Apr;8(4):e289-e298

Department of Haematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.

Background: Primary immune thrombocytopenia is an autoimmune bleeding disorder. Preclinical reports suggest that the sialidase inhibitor oseltamivir induces a platelet response in the treatment of immune thrombocytopenia. This study investigated the activity and safety of dexamethasone plus oseltamivir versus dexamethasone alone as initial treatment in adult patients with primary immune thrombocytopenia. Read More

View Article and Full-Text PDF

Looking long-term: an unmet need in immune thrombocytopenia.

Authors:
Cindy Neunert

Lancet Haematol 2021 04;8(4):e245-e246

Department of Pediatrics, Division of Pediatric Hematology, Oncology, and Stem Cell Transplant, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address:

View Article and Full-Text PDF

An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?

Front Pharmacol 2021 8;12:632677. Epub 2021 Mar 8.

Department of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore, India.

COVID-19 pandemic has spread worldwide at an exponential rate affecting millions of people instantaneously. Currently, various drugs are under investigation to treat an enormously increasing number of COVID-19 patients. This dreadful situation clearly demands an efficient strategy to quickly identify drugs for the successful treatment of COVID-19. Read More

View Article and Full-Text PDF